Certain events in a study will occur that may impact interpretation of key efficacy or safety endpoints. Establishing appropriate quality tolerance limits (QTLs) can help identify and mitigate the frequency and extent of such event occurrences early. Creating QTLs ensures the early placement of risk mitigation steps to avoid the risk of key study-level parameters or events exceeding the established tolerance limits at the end of the study.
In this white paper, learn how PPD has established a robust and well-integrated, cross-functional process to help its sponsors execute the QTL component of ICH E6 (R2) that includes clinicians, data analytics, statisticians and other disciplines involved in clinical trial design, conduct and final reporting.
To download the white paper, please complete the form below. Fields marked with
* are required.
Primary service area of interest
Select country… Afghanistan Albania Algeria Andorra Angola Antigua and Deps Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia Herzegovina Botswana Brazil Brunei Bulgaria Burkina Burundi Cambodia Cameroon Canada Cape Verde Central African Rep Chad Chile China Colombia Comoros Congo Congo (Democratic Rep) Costa Rica Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hungary Iceland India Indonesia Iran Iraq Ireland (Republic) Israel Italy Ivory Coast Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar(Burma) Namibia Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Romania Russian Federation Rwanda Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka St Kitts and Nevis St Lucia Sudan Suriname Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Yemen Zambia Zimbabwe
Pharmaceutical Product Development, LLC and its affiliates (together “PPD”) will use the information you provide on this page for the purpose of contacting you on this subject. Important information on how PPD handles personal data and what rights you may have under data privacy laws are included within PPD’s